Click on image to view larger version.

Figure 1 Flow chart of the study design. Anti-anginal medications were stopped during the run-in phase. Patients were assigned single-blind 17-beta-estradiol (E₂; 1 mg/day). On day 18 (D18), this was increased to 2 mg/day and continued for the remainder of the study. Randomization to vaginal progesterone gel (Crinone) or MPA occurred on day 28 (D28) and day 56 (D56). Exercise treadmill testing (ETT) was performed on day 0 (D0), D28, D38, D56 and D66. Long-dashed line = Crinone; short-dashed line = MPA.